There are several pipeline items in the half year releases that sound very promising and I hadn't seen in prior announcements...
Gamma camera PSMA product (ie allows prostate cancer staging in places that do not have a PET camera).
Radiomuclide therapy for multiple myeloma (alpha therapy so much much more effective)
Expanded role for the TLX-250cdx PET tracer for non-RCC cancer
novel use of PSMA bound to a visible dye so that surgeons can literally see fluorescent light showing the prostate cancer during the op.
PSMA based alpha therapy for metastatic prostate cancer.
A lot of novel and great ideas coming up!!
Great also to see a lot of Australian involvement in the pipeline. Australia is one of the leading nations for pushing the boundaries of theranostics / radionuclide therapy.
Ann: Half Year Shareholder Update, page-5
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.13 |
Change
-0.340(1.75%) |
Mkt cap ! $6.401B | |||
| Open | High | Low | Value | Volume |
| $19.41 | $19.46 | $18.81 | $121.0M | 6.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7316 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.13 | 6814 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |